Clinical Trial Update: Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety, tolerability, and antiviral activity of ANA598 when given with pegylated interferon and ribavirin in genotype-1 chronic he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ANA598 (ANA598)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HCV Infection | Phase 2 | Status: COMPLETED